Mylan Inc. Issued Patents for COPD

Mylan Inc. announced this morning that they have been issued several U.S. patents which cover the administration of a ready-to-use inhaler.  Mylan stated in a press release that the patents were directly granted to its subsidiary, Dey L.P., and that the company received a “Notice of Allowance” on another patent which they expect to be granted in the near future.

The issued patents protect Dey’s Perforomist Inhalation Solution, which is a treatment for chronic obstructive pulmonary disease.  Two of the patents are directed towards the compositions of “R-formoterol,” a specific form of the formoterol molecule, and its use.  Another patent covers the administration of formoterol in a storage stable composition.  These patents extend to the year 2021.

Once the patent is granted that received a “Notice of Allowance,” Dey will possess seven patents directed towards the composition and use of formoterol.  Dey also has additional patents pending directed to formoterol-containing compositions and their use in the treatment of respiratory conditions.